CD19 mbIL15-CXCR5 CAR-T

CD19 mbIL15-CXCR5 CAR-T is an experimental fourth-generation chimeric antigen receptor (CAR) T-cell therapy designed to treat B-cell malignancies, particularly B-cell lymphomas with bulky masses. The therapy utilizes an FMC63-derived single-chain variable fragment (scFv) to target the CD19 antigen, combined with 4-1BB costimulatory and CD3ζ signaling domains. It is uniquely engineered to co-express membrane-bound interleukin-15 (mbIL-15) and the chemokine receptor CXCR5. The mbIL-15 component is intended to enhance T-cell persistence, promote a central memory (TCM) and effector memory (TEM) phenotype, and provide sustained survival signals without the systemic toxicity associated with high-dose soluble IL-15. The CXCR5 modification is designed to improve the migration and infiltration of the CAR-T cells into tumor tissues by responding to CXCL13, a chemokine frequently overexpressed in the microenvironment of B-cell lymphomas. This dual-modification strategy aims to overcome therapeutic barriers such as poor tumor penetration and T-cell exhaustion.

Other names

fourth-generation CD19 CAR-T cells expressing mbIL-15 and CXCR5